TCF3 and pelvic inflammatory disease: New Zealand has also had a long-standing customised PID diagnostic genetic testing program, which has led to the discovery of two new genetic defects, autosomal dominant pathogenic variants of Nuclear Factor kappa-light-chain-enhancer of activated B cells (NFKB1) and Transcription Factor 3 (TCF3), consequent to haploinsufficiency [7–9].